nach oben

The European Journal of Health Economics

Erschienen in:

05.05.2020 | Editorial

Efficiency ratio and rocketing drug prices: old concerns and new possibilities

verfasst von: Stefano Capri, Fernando Antonanzas

Erschienen in: The European Journal of Health Economics | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Excerpt

One of the most significant phenomena in the recent years concerning the pharmaceutical industry and, at the same time, payers in healthcare systems, is the sharp acceleration in the growth of new drug prices [1]. …

Morgan, S.G., Bathula, H.S., Moon, S.: Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ 368, l4627 (2020). https://doi.org/10.1136/bmj.l4627CrossRefPubMed

Savage, P., Mahmoud, S.: Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014. Br. J. Cancer 112, 1037–1041 (2015)CrossRef

Kantarjian, H.M., Fojo, T., Mathisen, M., Zwelling, L.A.: Cancer drugs in the United States: justumpretium the just price. J. Clin. Oncol. 31(28), 3600–3604 (2013)CrossRef

Light, D.W., Kantarjian, H.: Market spiral pricing of cancer drugs. Cancer 119(22), 3900–3902 (2013)CrossRef

Wait, S., Han, D., Muthu, D., et al.: Towards sustainable cancer care. Reducing inefficiencies, improving outcomes. J. Cancer Policy 13, 47–64 (2017)CrossRef

Mailankody, S., Prasad, V.: Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 1(4), 530–540 (2015)CrossRef

Vivot, A., Jacot, J., Zeitoun, J.D., et al.: Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann. Oncol. 28, 1111–1116 (2017)CrossRef

Salas-Vega, S., Iliopoulos, O., Mossialos, E.: Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 3(3), 382–390 (2017)CrossRef

Aggarwal, A., Fojo, T., Chamberlain, C., Sullivan, S.: Do patient access schemes for high-cost cancer drugs deliver value to society?—Lessons from the NHS Cancer Drugs Fund. Ann. Oncol. 20, 1–13 (2017). https://doi.org/10.1093/annonc/mdx110CrossRef

10.

Naci, H., Salcher-Konrad, M., Kesselheim, A.S., Wieseler, B., Rochaix, L., Redberg, R.F., Salanti, G., Jackson, E., Garner, S., Stroup, S., Cipriani, A.: Generating comparative evidence on new drugs and devices before approval. Lancet 395(10228), 986–997 (2020)CrossRef

11.

Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., Aggarwal, A.: Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals-13. BMJ 359, 4530 (2009)

12.

Niraula, S., Nugent, Z.: New cancer drug approvals from the perspective of a universal healthcare system: analyses of the Pan-Canadian Oncology Drug Review Recommendations. J. Natl. Compr. Cancer. Netw. 16(12), 1460–1466 (2018)CrossRef

Titel: Efficiency ratio and rocketing drug prices: old concerns and new possibilities
verfasst von: Stefano Capri
Fernando Antonanzas
Publikationsdatum: 05.05.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 9/2020
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-020-01194-9

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Efficiency ratio and rocketing drug prices: old concerns and new possibilities

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Timing matters: worker absenteeism in a weekly backward rotating shift model

The impact of the diabetes management incentive on diabetes-related services: evidence from Ontario, Canada

Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany

HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies

Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas

General practitioners’ income and activity: the impact of multi-professional group practice in France